S 0034
Latest Information Update: 16 Jul 1998
Price :
$50 *
At a glance
- Originator Aventis
- Class Antihyperglycaemics; Cyclohexanes
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetes mellitus